Studies blood samples from people with unusual HIV patterns
Tests blood samples from adults with HIV who have unusual disease patterns.
Plain-language title generated from the registry record
Registry title: the ANRS CO21 " Extreme " Cohort (CODEX)
Key facts
- Where
- Le Kremlin-Bicêtre, FranceSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults living with HIV-1 who have an unusual course of infection. Groups include people who control the virus or keep stable CD4 counts without HIV treatment.
- Age
- 18 to 85 years
- Sex
- All sexes
- Disease stage
- HIV-1 infection, in one of four groups: stable or rising CD4 count above 600/mm3 for at least 8 years (ALT); viral load under 400 copies/mL on the last 5 tests, known for at least 5 years (HIC); both of these together (ALT HIC); or viral load kept under 400 copies/mL for 12 months or more after stopping HIV treatment (PTC).
- Earlier treatment
- ALT, HIC and ALT HIC groups: no HIV treatment (antiretroviral therapy). PTC group: HIV treatment started when viral load was above 2000 copies/mL, kept for at least 12 months, then stopped.
- Biomarker or test result
- HIV-1 infection without HIV-2. CD4 count above 600/mm3 (ALT groups). Viral load under 400 copies/mL (HIC, ALT HIC and PTC groups).
Main reasons for not taking part
- Co-infection with HIV-2
- People under legal protection (protection de justice)
- People not covered by French Social Security
- People unable to give written consent
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 85 years old?
Source: NCT01520844, who can take part
Where in France
- LambotteLe Kremlin-Bicêtre, FranceContact: Olivier Lambotte, ProfessorTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- ANRS, Emerging Infectious Diseases
- Trial code
- NCT01520844
- Record updated
- 7 April 2026
- Original description
A consortium of research teams has studied the immunovirological characteristics of these patients:Read full original descriptionShow less
Multicentric Cohort of HIV Patient With Extrem Profil
A consortium of research teams has studied the immunovirological characteristics of these patients:
The ANRS CO15 ALT cohort The ANRS CO18 HIV Controller cohort the ANRS EP47 VISCONTI study
Inclusion: Patient infected with HIV-1 and not co-infected with HIV-2; Age ≥ 18 at enrollment; Able to give written consent; Covered by French Social Security; accept the constraints imposed by the study; without antiretroviral therapy for ALT, HIC and ALT HIC groups and a control of viral load after antiretroviral treatment interruption in PTC group; ALT group: Documented HIV-1 seropositive for at least 8 years with a CD4 count above 600/mm3 with a rate stable or increasing (positive or zero slope) on at least three consecutive examinations performed during the last 5 years regardless of the viral load in the absence of antiretroviral treatment; HIC group: HIV-1 Seropositivity known for at least five years, asymptomatic, with the last 5 viral loads in HIV-RNA consecutive <400 copies / mL regardless of CD4 count in the absence of antiretroviral treatment; ALT HIC group: HIV-1 seropositive known for at least 8 years and CD4 cell counts greater than 600/mm3 with a rate stable or increasing (positive or zero slope) on at least three consecutive examinations performed during the last 5 years and with the last 5 viral loads in HIV-RNA consecutive <400 copies / mL in the absence of antiretroviral therapy; PTC group: Patients with plasma HIV RNA > 2000 copies/mL before initiation of antiretroviral therapy. Treatment started during the primary infection (as defined by symptoms associated with seroconversion, as confirmed by a first negative ELISA and/or an incomplete P24-positive Western blot) or during the chronic phase of infection, and maintained for at least 12 months in both cases. Control of viral load after antiretroviral treatment interruption: patients must have at least two available viral load assays after stopping antiretroviral therapy. All viral loads must be <400 copies/mL for 12 months or more after stopping antiretroviral therapy, with the possible exception of one blip (one viral load above 400 copies/mL between two viral loads <400 copies/mL at least one month apart from the blip; in this case at least three viral load assays will be required). The last plasma viral load value at the time of inclusion must always be <400 copies/mL.
Exclusion: Under protection(saving) of justice.